# A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia

> **NCT06079398** · PHASE2 · RECRUITING · sponsor: **Ascendis Pharma A/S** · enrollment: 72 (estimated)

## Conditions studied

- Achondroplasia

## Interventions

- **DRUG:** Navepegritide
- **DRUG:** Placebo for Navepegritide

## Key facts

- **NCT ID:** NCT06079398
- **Lead sponsor:** Ascendis Pharma A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-23
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06079398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06079398, "A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06079398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*